Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-04-17 | Stephen J. Aselage was appointed to the Board in January 2019. ... The Compensation Committee, currently consisting of Dr. Hutson, as its Chairwoman, Mr. Ingram and Mr. Aselage. |
| 2020-03-31 | Stephen J. Aselage was appointed to the Board in January 2019. Until January 2019, Mr. Aselage served as Chief Executive Officer of Retrophin Inc., a publicly traded biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease, which he joined in 2012. ... The Company has a Compensation Committee, currently consisting of Dr. Hutson, as its Chairwoman, Mr. Ingram and Mr. Aselage. ... The Company has an Audit Committee, currently consisting of Mr. Lee, as its Chairman, Mr. Abercrombie, Ms. Heggie, and Mr. Levin. ... 2019 DIRECTOR COMPENSATION ... The following table provides information related to the compensation of our non-employee directors during fiscal 2019. ... Stephen J. Aselage 74,375 205,813 – – 280,185 ... The Compensation Committee currently consists of Dr. Hutson, as its Chairwoman, Mr. Ingram and Mr. Aselage. |
| 2021-04-13 | Stephen J. Aselage was initially appointed to the Board in January 2019. ... The Company has a Compensation Committee, currently consisting of Dr. Hutson, Mr. Aselage, and Mr. Ingram. ... 2020 DIRECTOR COMPENSATION ... Stephen J. Aselage 220,935 |
| 2023-04-27 | Stephen J. Aselage was initially appointed to the Board in January 2019... The Company’s Audit Committee currently consists of Mr. Lee, as its Chair, Mr. Abercrombie, Ms. Heggie (since February 2023), Mr. Levin, and Mr. Milano... The Company’s Compensation Committee currently consists of Dr. Hutson, as its Chair, Mr. Aselage, and Ms. Sanders (since February 2023)... 2022 Director Compensation: Stephen J. Aselage total compensation $447,348. |
Data sourced from SEC filings. Last updated: 2026-02-03